1-228158352-C-T
Position:
Variant summary
Our verdict is Benign. Variant got -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BS1BS2
The NM_020435.4(GJC2):c.594C>T(p.His198His) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0379 in 1,588,150 control chromosomes in the GnomAD database, including 1,331 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).
Frequency
Genomes: 𝑓 0.025 ( 68 hom., cov: 32)
Exomes 𝑓: 0.039 ( 1263 hom. )
Consequence
GJC2
NM_020435.4 synonymous
NM_020435.4 synonymous
Scores
2
Clinical Significance
Conservation
PhyloP100: -0.273
Genes affected
GJC2 (HGNC:17494): (gap junction protein gamma 2) This gene encodes a gap junction protein. Gap junction proteins are members of a large family of homologous connexins and comprise 4 transmembrane, 2 extracellular, and 3 cytoplasmic domains. This gene plays a key role in central myelination and is involved in peripheral myelination in humans. Defects in this gene are the cause of autosomal recessive Pelizaeus-Merzbacher-like disease-1. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -21 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.51).
BP6
Variant 1-228158352-C-T is Benign according to our data. Variant chr1-228158352-C-T is described in ClinVar as [Benign]. Clinvar id is 241298.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr1-228158352-C-T is described in Lovd as [Benign].
BP7
Synonymous conserved (PhyloP=-0.273 with no splicing effect.
BS1
Variant frequency is greater than expected in population nfe. gnomad4 allele frequency = 0.0251 (3808/151878) while in subpopulation NFE AF= 0.0417 (2834/67902). AF 95% confidence interval is 0.0405. There are 68 homozygotes in gnomad4. There are 1761 alleles in male gnomad4 subpopulation. Median coverage is 32. This position pass quality control queck.
BS2
High Homozygotes in GnomAd4 at 68 AD,AR gene
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GJC2 | NM_020435.4 | c.594C>T | p.His198His | synonymous_variant | 2/2 | ENST00000366714.3 | NP_065168.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GJC2 | ENST00000366714.3 | c.594C>T | p.His198His | synonymous_variant | 2/2 | 1 | NM_020435.4 | ENSP00000355675.2 |
Frequencies
GnomAD3 genomes AF: 0.0251 AC: 3813AN: 151764Hom.: 69 Cov.: 32
GnomAD3 genomes
AF:
AC:
3813
AN:
151764
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0294 AC: 6109AN: 207860Hom.: 147 AF XY: 0.0313 AC XY: 3583AN XY: 114606
GnomAD3 exomes
AF:
AC:
6109
AN:
207860
Hom.:
AF XY:
AC XY:
3583
AN XY:
114606
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0393 AC: 56385AN: 1436272Hom.: 1263 Cov.: 36 AF XY: 0.0396 AC XY: 28255AN XY: 713512
GnomAD4 exome
AF:
AC:
56385
AN:
1436272
Hom.:
Cov.:
36
AF XY:
AC XY:
28255
AN XY:
713512
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0251 AC: 3808AN: 151878Hom.: 68 Cov.: 32 AF XY: 0.0237 AC XY: 1761AN XY: 74254
GnomAD4 genome
AF:
AC:
3808
AN:
151878
Hom.:
Cov.:
32
AF XY:
AC XY:
1761
AN XY:
74254
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
55
AN:
3466
ClinVar
Significance: Benign
Submissions summary: Benign:6
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not specified Benign:3
Benign, criteria provided, single submitter | clinical testing | Athena Diagnostics | Dec 26, 2019 | - - |
Benign, criteria provided, single submitter | clinical testing | GeneDx | Jul 06, 2016 | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. - |
Benign, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | - | - - |
Spastic paraplegia Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 31, 2024 | - - |
Hereditary spastic paraplegia Benign:1
Benign, criteria provided, single submitter | clinical testing | Genome Diagnostics Laboratory, The Hospital for Sick Children | Jan 20, 2022 | - - |
not provided Benign:1
Benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at